



(51) International Patent Classification:

A61K 31/49 (2006.01) *G01N 33/00* (2006.01)

(21) International Application Number:

PCT/EP2020/074860

(22) International Filing Date:

04 September 2020 (04.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: **PHARMA MAR, S.A.** [ES/ES]; Polígono Industrial La Mina, Avda. de los Reyes, 1, Colmenar Viejo, 28770 Madrid (ES).(72) Inventors: **KROEMER, Guido**; Gustave Roussy, BioCell platform, 114 rue Edouard Vaillant, 94805 Villejuif (FR).
KEPP, Olivier; Gustave Roussy, BioCell platform, 114 rue Edouard Vaillant, 94805 Villejuif (FR).(74) Agent: **MARKS & CLERK LLP**; 62-68 Hills Road, Cambridge CB2 1LA (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))

Published:

— with international search report (Art. 21(3))

(54) Title: COMBINATION OF LURBINECTEDIN AND IMMUNE CHECKPOINT INHIBITOR




FIGURE 6

(57) Abstract: Described are combination therapies for the treatment of solid tumours, said therapies comprising lurbinectedin and an immune checkpoint inhibitor, for example, anti-PD-1, anti-PD-L1 or anti-CTLA-4 antibodies.